Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment Options.
Diabetes mellitus (DM) is also a cause of cardiovascular (CV) disease (CVD). Addressing the atherosclerotic CVD (ASCVD) burden in DM should reduce premature death and improve quality of life. Diabetes mellitus-associated ASCVD can lead to complications in all vascular beds (carotids as well as coronary, lower extremity, and renal arteries). This narrative review considers the diagnosis and pharmacological treatment of noncardiac atherosclerotic vascular disease (mainly in patients with DM). Based on current knowledge and the fact that modern DM treatment guidelines are based on CV outcome trials, it should be noted that patients with noncardiac CVD may not have the same benefits from certain drugs compared with patients who predominantly have cardiac complications. This leads to the conclusion that in the future, consideration should be given to conducting well-designed trials that will answer which pharmacological treatment modalities will be of greatest benefit to patients with noncardiac ASCVD.
['Muzurović|Emir M|EM|0000-0003-2022-3298', 'Mikhailidis|Dimitri P|DP|']
D000818:Animals D001014:Aortic Aneurysm D002317:Cardiovascular Agents D003920:Diabetes Mellitus D006801:Humans D007004:Hypoglycemic Agents D058729:Peripheral Arterial Disease D012078:Renal Artery Obstruction D018570:Risk Assessment D012307:Risk Factors D020521:Stroke D016896:Treatment Outcome
diabetes mellitus pharmacological treatment noncardiac atherosclerotic vascular disease aortic aneurysm cardiovascular outcome trials peripheral artery disease renal artery stenosis stroke